Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06064734
Other study ID # HX-A-2023001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 28, 2023
Est. completion date October 30, 2024

Study information

Verified date September 2023
Source Beijing Tiantan Hospital
Contact Zixiao Li, MD
Phone 86-13683234256
Email lizixiao2008@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, open-label, evaluator-blinded, investigator-initiated, randomized clinical trial, to evaluate the clinical efficacy and safety of LF-rTMS in reducing infarct size, reducing disability rate and improving functional outcome in patients with acute ischemic stroke within 48 hours after stroke onset.


Description:

The target population of this study was patients with clinically diagnosed AIS who had an acute occlusion of the responsible vessel in the anterior circulation and were not scheduled for intravenous thrombolysis and/or endovascular therapy, the time from stroke onset to the start of study intervention was less than 48-hours. Enrolled patients were randomly assigned in a 1:1 ratio to either the"LF-rTMS group" or the"Control group" to receive: 1. LF-rTMS group: H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses). 2. Control group: received routine treatment. All the above therapeutic interventions were conducted by trained TMS operators. Except for the study intervention, the subjects in both groups received clinical routine diagnosis and treatment which were not affected by the intervention. All patients were followed up until the 90th day after randomization to evaluate the clinical efficacy and safety of LF-rTMS in reducing infarct size, reducing disability rate and improving functional outcome in patients with acute ischemic stroke within 48 hours after stroke onset.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date October 30, 2024
Est. primary completion date October 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age 18-80 years, gender is not limited; 2. Acute ischemic stroke of anterior circulation was diagnosed clinically 3. mRS 0-1 score before onset; 4. 6 = NIHSS =25 at randomization; 5. Within 48 hours of stroke onset; 6. No thrombolysis therapy or thrombectomy is planned; 7. Obtain informed consent signed by the patient himself or by his legal authorized representative. Exclusion Criteria: 1. TMS contraindications include metallic foreign bodies in the head, pacemaker, implantable drug pumps, cochlear implants, etc. 2. Epilepsy or history of epilepsy, intracranial hypertension, tumor and other serious neurological disorders; 3. Midline displacement and brain parenchymal mass effect seen in head CT and other images; 4. Head CT or MRI showed bilateral acute cerebral infarction and involved insular infarction; 5. Evidence of acute intracranial hemorrhage; 6. A history of congenital or acquired hemorrhagic disease, coagulation factor deficiency, or thrombocytopenia disease; 7. After blood pressure control, the systolic blood pressure was still =180 mmHg or the diastolic blood pressure was =110 mmHg; 8. Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal or estimated glomerular filtration rate (EGFR) < 60 mL/min; 9. Patients during pregnancy or lactation and within 90 days of planned pregnancy; 10. Patients with severe mental disorders or dementia who can not cooperate with informed consent and follow-up; 11. Patients with malignancy or severe systemic disease and expected survival of less than 90 days; 12. Participants in other clinical intervention studies within 30 days before randomization or who were participating in other clinical intervention studies.

Study Design


Intervention

Device:
LF-rTMS
H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval =2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).

Locations

Country Name City State
China Beijing Tian tan Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Tiantan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Infarct growth Infarct growth at 3 days was calculated as the absolute difference between the baseline core infarct volume and the 3 days post-randomization infarct volume. 3 days
Primary Proportion of Early neurological improvement (ENI) Proportion of patients with a reduction of =4 on the NIHSS, compared with the baseline score or an NIHSS of 0 or 1 3 days
Primary Symptomatic intracranial hemorrhage The proportion of symptomatic intracranial hemorrhage 3 days
Secondary Final infarct volume Final infarct volume 3 days
Secondary ?NIHSS score Change in NIHSS score from baseline 3 days
Secondary mRS scores of 0-1 Proportion of patients with mRS scores of 0-1 90 days
Secondary mRS scores of 0-2 Proportion of patients with mRS scores of 0-2 90 days
Secondary Barthel index of ADL Barthel index of ADL, 0-100 (better) 90 days
Secondary EQ-5D-5L The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" through "extreme problems." 90 days
Secondary Montreal Cognitive Assessment (MoCA) total score Total score of the MoCA Performance on the MoCA (0-30; higher score indicates better performance) 90 days
Secondary Serious adverse events The proportion of serious adverse events (SAE) 90 days
Secondary All-cause deaths The proportion of all-cause deaths 90 days
Secondary Symptomatic intracranial hemorrhage The incidence of symptomatic intracranial hemorrhage 90 days
Secondary Deterioration of neurological function The incidence of deterioration of neurological function (NIHSS increase =4 points) 3 days
Secondary Stroke recurrence Recurrence rate of symptomatic stroke (cerebral infarction, cerebral hemorrhage) 90 days
Secondary Adverse events (AE) The proportion of adverse events (AE) 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Completed NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke N/A
Completed NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Completed NCT03633422 - Evaluation of Stroke Patient Screening
Completed NCT04088578 - VNS-supplemented Motor Retraining After Stroke N/A
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Not yet recruiting NCT05534360 - Tenecteplase Treatment in Ischemic Stroke Registry
Not yet recruiting NCT04105322 - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients N/A
Withdrawn NCT05786170 - ERILs Und SNILs Unter SOC N/A
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Completed NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS)
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT05760326 - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients